Takeda Type II diabetes drug shown useful in late-stage trial

09/13/2005 | Wall Street Journal, The

Researchers report that Takeda Pharmaceuticals' Actos proved effective in a late-stage trial in reducing the risk of fatal or serious conditions associated with Type II diabetes. In conjunction with Eli Lilly, Takeda has been developing the drug, which the companies said reduced the combined risk of heart attacks, strokes and death by 16%.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC